Optimized antigens of pneumocystis and use thereof

US9512189B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9512189-B2
Application numberUS-201214237133-A
CountryUS
Kind codeB2
Filing dateAug 6, 2012
Priority dateAug 4, 2011
Publication dateDec 6, 2016
Grant dateDec 6, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Immunologically active agents are described, including isolated Pneumocystis A 12 protein or polypeptides; immunogenic conjugates containing Pneumocystis A 12 protein or polypeptide of the present invention; antibodies recognizing the Pneumocystis A 12 protein or polypeptide or the immunogenic conjugates of the present invention; and nucleic acid molecules that encode the Pneumocystis A 12 protein or polypeptide of the present invention, as well as DNA constructs, expression vectors, and host cells that contain the nucleic acid molecules. Disclosed uses of the antibodies, immunogenic conjugates, and DNA constructs include inducing passive or active immunity to treat or prevent pathogen infections, particularly by a Pneumocystis organism, in a subject.

First claim

Opening claim text (preview).

What is claimed is: 1. An isolated Pneumocystis A12 protein or polypeptide fragment comprising an amino acid sequence that is at least 90% identical to at least a 40 contiguous amino acid sequence of SEQ ID NO:2. 2. A vaccine comprising the isolated protein or polypeptide according to claim 1 . 3. A pharmaceutical composition comprising: the isolated protein or polypeptide according to claim 1 and a pharmaceutically acceptable carrier. 4. A vaccine comprising a fusion protein comprising: a first protein or protein fragment comprising an N-terminal region of Pneumocystis A12 and a second protein or protein fragment linked to the first protein or protein fragment. 5. A pharmaceutical composition comprising: a fusion protein comprising: a first protein or protein fragment comprising an N-terminal region of Pneumocystis A12 and a second protein or protein fragment linked to the first protein or protein fragment and a pharmaceutically acceptable carrier.

Assignees

Inventors

Classifications

  • Immunostimulants · CPC title

  • from protozoa · CPC title

  • Emulsions, e.g. Freund's adjuvant, MF59 · CPC title

  • Fungal antigens, e.g. Trichophyton, Aspergillus, Candida · CPC title

  • Antimycotics · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9512189B2 cover?
Immunologically active agents are described, including isolated Pneumocystis A 12 protein or polypeptides; immunogenic conjugates containing Pneumocystis A 12 protein or polypeptide of the present invention; antibodies recognizing the Pneumocystis A 12 protein or polypeptide or the immunogenic conjugates of the present invention; and nucleic acid molecules that encode the Pneumocystis A…
Who is the assignee on this patent?
Gigliotti Francis, Wright Terry W, Haidaris Constantine G, and 2 more
What technology area does this patent fall under?
Primary CPC classification A61K39/0002. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).